We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Continue to Hold Ensign Group Stock
Read MoreHide Full Article
Key Takeaways
Ensign benefits from rising occupancy, patient volumes and strong post-acute care demand.
ENSG added five operations, signed deals for 17 more and posted strong occupancy gains.
Standard Bearer rental revenues rose 27.1% as owned real estate assets reached 160.
The Ensign Group, Inc. (ENSG - Free Report) remains well positioned to benefit from favorable demographic and post-acute care trends, supported by rising occupancy and patient volumes. Headquartered in San Juan Capistrano, CA, the company operates through its Skilled Services and Standard Bearer segments.
Following recent acquisitions, Ensign's portfolio has expanded to approximately 396 healthcare operations, including 48 senior living operations, across 17 states. It holds a market capitalization of around $9.14 billion. ENSG has risen 3.9% over the past year compared with the industry’s average gain of 4.1%. ENSG currently holds a Zacks Rank #3 (Hold).
Where Do Estimates for ENSG Stand?
The Zacks Consensus Estimate for Ensign Group’s 2026 earnings is pegged at $7.48 per share, indicating a 13.9% year-over-year rise. The consensus mark for revenues is pegged at $5.82 billion for 2026, implying 15% year-over-year growth. It beat earnings estimates in each of the past four quarters, with an average surprise of 3.4%.
The Ensign Group, Inc. Price, Consensus and EPS Surprise
Ensign continues to benefit from robust demand for post-acute care services, translating into higher patient volumes and occupancy gains. In the first quarter of 2026, same-store occupancy improved 190 basis points year over year to 84.3%, while transitioning-facility occupancy increased 310 basis points to 85.1%. Skilled revenues and skilled patient days at transitioning operations rose 9.6% and 8.5%, respectively, reflecting strong underlying demand and successful operational integration.
Strategic acquisitions remain a core growth pillar for Ensign. The company added five stand-alone skilled nursing operations in the first quarter of 2026 and signed agreements for 17 additional facilities. Its proven ability to integrate acquisitions, improve clinical performance and strengthen referral relationships supports higher occupancy, patient volumes and earnings growth. Ensign's ROIC of 8.1% significantly exceeds the industry average of 3.1%, highlighting the effectiveness of its growth strategy and capital allocation.
Beyond operating skilled nursing facilities, Ensign continues to expand its real estate portfolio through its Standard Bearer segment. As of March 31, 2026, the company owned 160 real estate assets, providing greater control over occupancy costs and creating an additional stream of rental income primarily from its own operating subsidiaries. During the first quarter of 2026, Standard Bearer rental revenues increased 27.1% year over year to $36.1 million, while segment income rose 25.9%. ENSG's strategy of pairing healthcare operations with selective real estate ownership strengthens cash-flow generation enhances returns on acquisitions, and provides another powerful avenue for long-term earnings growth.
Ensign's balance sheet remains a competitive advantage. The company ended the first quarter of 2026 with $539.5 million in cash and cash equivalents against only $136.5 million in long-term debt. It had approximately $592 million of available borrowing capacity under its revolving credit facility. Strong operating cash flow of $100.2 million provides ample flexibility to fund acquisitions, invest in existing operations and pursue real estate purchases without materially increasing leverage. Additionally, $20 million remained available under its share repurchase authorization as of March 31, 2026. Reflecting its conservative financial profile, total debt represented just 5.6% of capital, substantially below the industry average of 89.3%.
ENSG: Risks to Watch
There are some factors, however, that investors should keep a careful eye on.
Ensign remains exposed to reimbursement uncertainty, as Medicare and Medicaid accounted for 69.1% of service revenues in the first quarter of 2026. Consequently, changes in reimbursement rates, regulatory policies or payer reviews could adversely impact profitability. Competition for acquisitions, labor and patient referrals remains intense across the fragmented post-acute care industry. Heightened competitive pressures could increase operating costs, raise acquisition multiples and constrain occupancy growth.
Ensign has experienced steady cost inflation in recent years, driven primarily by higher service and rent expenses. Total expenses increased 12.3% in 2024 and 18.7% in 2025, followed by an 18.0% year-over-year rise to $1.26 billion in the first quarter of 2026. If expense growth continues to outpace revenue gains, it could pressure margins and limit earnings growth.
The Zacks Consensus Estimate for Indivior Pharmaceuticals’ 2026 earnings is pegged at $4.05 per share, indicating a 62% year-over-year improvement. INDV beat earnings estimates in each of the trailing four quarters, with the average surprise being 65.44%. The consensus estimate for 2026 revenues is pinned at $1.26 billion, implying 1.5% year-over-year growth.
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.47 per share, indicating 66.8% year-over-year growth. It has witnessed nine upward revisions in the past 60 days, with no movement in the opposite direction. CNC beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 74.9%. The consensus estimate for 2026 revenues is pinned at $191.03 billion.
The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.67 per share, which has witnessed five upward revisions in the past 60 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 14.6%. The consensus estimate for 2026 revenues is pinned at $15.05 billion, implying 16.6% year-over-year growth.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Investors Continue to Hold Ensign Group Stock
Key Takeaways
The Ensign Group, Inc. (ENSG - Free Report) remains well positioned to benefit from favorable demographic and post-acute care trends, supported by rising occupancy and patient volumes. Headquartered in San Juan Capistrano, CA, the company operates through its Skilled Services and Standard Bearer segments.
Following recent acquisitions, Ensign's portfolio has expanded to approximately 396 healthcare operations, including 48 senior living operations, across 17 states. It holds a market capitalization of around $9.14 billion. ENSG has risen 3.9% over the past year compared with the industry’s average gain of 4.1%. ENSG currently holds a Zacks Rank #3 (Hold).
Where Do Estimates for ENSG Stand?
The Zacks Consensus Estimate for Ensign Group’s 2026 earnings is pegged at $7.48 per share, indicating a 13.9% year-over-year rise. The consensus mark for revenues is pegged at $5.82 billion for 2026, implying 15% year-over-year growth. It beat earnings estimates in each of the past four quarters, with an average surprise of 3.4%.
The Ensign Group, Inc. Price, Consensus and EPS Surprise
The Ensign Group, Inc. price-consensus-eps-surprise-chart | The Ensign Group, Inc. Quote
ENSG’s Growth Drivers
Ensign continues to benefit from robust demand for post-acute care services, translating into higher patient volumes and occupancy gains. In the first quarter of 2026, same-store occupancy improved 190 basis points year over year to 84.3%, while transitioning-facility occupancy increased 310 basis points to 85.1%. Skilled revenues and skilled patient days at transitioning operations rose 9.6% and 8.5%, respectively, reflecting strong underlying demand and successful operational integration.
Strategic acquisitions remain a core growth pillar for Ensign. The company added five stand-alone skilled nursing operations in the first quarter of 2026 and signed agreements for 17 additional facilities. Its proven ability to integrate acquisitions, improve clinical performance and strengthen referral relationships supports higher occupancy, patient volumes and earnings growth. Ensign's ROIC of 8.1% significantly exceeds the industry average of 3.1%, highlighting the effectiveness of its growth strategy and capital allocation.
Beyond operating skilled nursing facilities, Ensign continues to expand its real estate portfolio through its Standard Bearer segment. As of March 31, 2026, the company owned 160 real estate assets, providing greater control over occupancy costs and creating an additional stream of rental income primarily from its own operating subsidiaries. During the first quarter of 2026, Standard Bearer rental revenues increased 27.1% year over year to $36.1 million, while segment income rose 25.9%. ENSG's strategy of pairing healthcare operations with selective real estate ownership strengthens cash-flow generation enhances returns on acquisitions, and provides another powerful avenue for long-term earnings growth.
Ensign's balance sheet remains a competitive advantage. The company ended the first quarter of 2026 with $539.5 million in cash and cash equivalents against only $136.5 million in long-term debt. It had approximately $592 million of available borrowing capacity under its revolving credit facility. Strong operating cash flow of $100.2 million provides ample flexibility to fund acquisitions, invest in existing operations and pursue real estate purchases without materially increasing leverage. Additionally, $20 million remained available under its share repurchase authorization as of March 31, 2026. Reflecting its conservative financial profile, total debt represented just 5.6% of capital, substantially below the industry average of 89.3%.
ENSG: Risks to Watch
There are some factors, however, that investors should keep a careful eye on.
Ensign remains exposed to reimbursement uncertainty, as Medicare and Medicaid accounted for 69.1% of service revenues in the first quarter of 2026. Consequently, changes in reimbursement rates, regulatory policies or payer reviews could adversely impact profitability. Competition for acquisitions, labor and patient referrals remains intense across the fragmented post-acute care industry. Heightened competitive pressures could increase operating costs, raise acquisition multiples and constrain occupancy growth.
Ensign has experienced steady cost inflation in recent years, driven primarily by higher service and rent expenses. Total expenses increased 12.3% in 2024 and 18.7% in 2025, followed by an 18.0% year-over-year rise to $1.26 billion in the first quarter of 2026. If expense growth continues to outpace revenue gains, it could pressure margins and limit earnings growth.
Stocks to Consider
Some better-ranked stocks in the broader Medical space are Indivior Pharmaceuticals, Inc. (INDV - Free Report) , Centene Corporation (CNC - Free Report) and BrightSpring Health Services, Inc. (BTSG - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Indivior Pharmaceuticals’ 2026 earnings is pegged at $4.05 per share, indicating a 62% year-over-year improvement. INDV beat earnings estimates in each of the trailing four quarters, with the average surprise being 65.44%. The consensus estimate for 2026 revenues is pinned at $1.26 billion, implying 1.5% year-over-year growth.
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.47 per share, indicating 66.8% year-over-year growth. It has witnessed nine upward revisions in the past 60 days, with no movement in the opposite direction. CNC beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 74.9%. The consensus estimate for 2026 revenues is pinned at $191.03 billion.
The Zacks Consensus Estimate for BrightSpring Health’s 2026 earnings is pegged at $1.67 per share, which has witnessed five upward revisions in the past 60 days, with no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 14.6%. The consensus estimate for 2026 revenues is pinned at $15.05 billion, implying 16.6% year-over-year growth.